Drug Trial Radar · NCT05389449
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Actual
Start
Oct 28, 2022
Primary completion
Aug 24, 2026
Study completion Aug 24, 2026
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
DanicopanDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEsTime frame: Up to 3 years
Locations
45 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Kansas City, Missouri
Research Site
Long Island City, New York
Research Site
Cleveland, Ohio
Research Site
Dallas, Texas
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Toronto, Ontario, Canada
Research Site
Brno, Czechia
Research Site
Lille, France
Research Site
Paris, France
Research Site
Pessac, France
Research Site
Pierre-Bénite, France
Research Site
Athens, Greece
Research Site
Thessaloniki, Greece
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Avellino, Italy
Research Site
Bassano del Grappa, Italy
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Reggio Calabria, Italy
Research Site
Roma, Italy
Research Site
Bunkyō City, Japan
Research Site
Kyoto, Japan
Research Site
Osaka, Japan
Research Site
Shibuya-ku, Japan
Research Site
Tsukuba, Japan
Research Site
Kota Kinabalu, Malaysia
Research Site
Kuching, Malaysia
Research Site
Miri, Malaysia
Research Site
Gdansk, Poland
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Research Site
Badalona, Spain
Research Site
Barcelona, Spain
Research Site
Majadahonda, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.